Cancer Research UK and Cancer Research Technology are to join forces with big pharma, Astellas Pharma to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.

Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.

The first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells.

For further deal information visit Current Agreements (subscription required)

Related

Report: Partnering Deals and Alliances with Astellas

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter